In short: both have real research behind them, and in both cases that research was mostly done in a different form from the one cosmetics sell. The deciding question isn't "does it work?" but "does it work applied to intact skin?" – and there the evidence is far thinner than the volume of conversation suggests.
Exosomes. Tiny vesicles that cells use to communicate with each other, carrying signals. The idea is that applying them delivers regenerative instructions to the skin. They're sourced from different origins – stem cells, plants, ferments – and that source changes a great deal about what we're even discussing.
PDRN. Fragments of DNA, usually salmon-derived, proposed as stimulators of tissue repair.
Both mechanisms are real and studied. The problem isn't in the biology.
Both share the same obstacle, and it's the one that explains almost all the reasonable scepticism:
They're large molecules. The skin barrier exists precisely to keep large things out. A vesicle or a DNA fragment has to cross the intact stratum corneum to do anything in the layers where it's supposed to act.
And most of the research wasn't done that way. It was done after a procedure that removes or perforates the surface, or by a route that isn't a cream. Under those conditions the compound gets in. In a cream on intact skin, the evidence that it gets in is much weaker.
Our register grades exosomes at C overall – and drops to D specifically for the "regenerative transformation" claim from a topical exosome, because for that particular promise there's no topical evidence to hold it up.
It doesn't mean they're a fraud. It means the impressive evidence being cited corresponds to a different use than the one you're buying.
It's exactly the second question from reading a label – what concentration, and does the evidence match this form – applied to the two ingredients where it matters most right now.
In cosmetics there's a clear line between what a product can do and what it can claim. A cosmetic acts on the appearance of skin; claiming it regenerates tissue or repairs structures moves into medical-device or medicine territory, with a different legal framework.
When a cream promises effects of that magnitude, it isn't only exaggerating: it's describing something that, if true, wouldn't be a cosmetic.
If a product with exosomes or PDRN appeals to you, has a good moisturising base, and you tolerate it well, there's no reason to drop it. What makes no sense is to replace something with solid evidence – a retinoid, niacinamide, sunscreen – with it, expecting a bigger result.
That substitution is the real cost of the trend: not the money for the jar, but the months you weren't using what actually works.
The mechanism is real, but the evidence for a cream on intact skin is thin. Exosomes are large vesicles, and the skin barrier is built to keep large molecules out; most of the research showing benefit used a route that bypasses that barrier – after a procedure that breaks the surface, or by injection – not a leave-on cream. So the honest answer is that exosomes have genuine science behind them in the settings they were studied, and much weaker evidence for the topical form most products sell. Our register grades them C overall, dropping to D for the specific claim of "regenerative transformation" from a topical exosome.
PDRN is fragments of DNA, usually salmon-derived, proposed to stimulate tissue repair. Like exosomes, the underlying biology is studied, but much of the supporting work used injected or procedure-assisted delivery rather than a cream on intact skin. As a topical, the evidence that it penetrates and does what's claimed is limited. It isn't a fraud – it's a real molecule with real research in a form that isn't the one on the shelf.
If you like a product that contains them, tolerate it well, and it has a good moisturising base, there's no harm in using it. The mistake is replacing an ingredient with strong evidence – a retinoid, niacinamide, sunscreen – with one of these expecting a larger result. The real cost of a trend isn't the price of the jar; it's the months spent not using what's actually proven.
Partly because the biology is genuinely exciting, and partly because the impressive studies get cited without the caveat that they used a different delivery route. There's also a regulatory line worth knowing: a cosmetic acts on the appearance of skin, while claims to regenerate tissue or repair structures belong to medicines or medical devices. A cream promising effects of that scale is describing something that, if true, wouldn't legally be a cosmetic.
This is a neutral, educational cosmetic reference from Vallydia. It concerns the appearance of skin and is not medical advice.
Full evidence breakdown: Exosomes · how we grade.
Vallydia sells its own cosmetic serums, and some ingredients discussed here belong to the same categories as those products. Assessments are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Brand and trade names appearing in these articles are the property of their respective owners and are used only to identify the product or ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor. Where we judge a claim, we are judging the published evidence for that claim — not making a statement about the company that makes it.
A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.